The Role of Medications in Enhancing Patients' Overall Well-being and Quality of Life in Coronary Slow Flow syndrome: A Randomized Controlled Trial.

Background: Coronary slow flow syndrome or phenomenon (CSFP) is a coronary artery disease that may cause cardiac ischemia, symptoms, and related complications. This study, conducted as a randomized controlled trial, assessed and compared the effects of a treatment plan comprising aspirin, statin, nitrate, and Nicorandil on the quality of life of patients with CSFP. Methods: Out of 963 patients who underwent coronary angiography at Booalisina University Hospital in Qazvin, 52 individuals diagnosed with primary CSFP were enrolled in the study. They were randomly divided into two groups, with one receiving a three-drug treatment with 80 mg of aspirin, 20 mg of atorvastatin daily, and 2.6 mg of nitroglycerin every 12 hours (26 patients) and in the second group plus nicorandil 10 mg every 12 hours (26 patients). After two months, the patient's QOL was evaluated and compared using McNew's quality of life questionnaire. The SPSS version 16 software was used for data analysis. Results: In both groups, after two months, the QOL scores in physical, emotional, social, and overall (P<0.001) were significantly improved compared to the baseline (before the treatment). The comparison between the two groups revealed no statistically significant differences in emotional, social, or overall quality of life scores, but the physical dimension of the quality of life in the group who received nicorandil showed more improvement than the other group (P=0.032). Conclusion: A combination therapy of aspirin, atorvastatin, and nitrates has been demonstrated to significantly improve the quality of life in patients with Coronary Slow Flow Phenomenon (CSFP). However, the addition of nicorandil to this regimen does not provide significant further improvement, according to present findings.